


## **Cost Comparison Appraisal**

# Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]

## **Final Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
<ul> <li>Outlook Therapeutics Limited (bevacizumab gamma)</li> <li>Patient/carer groups</li> <li>Eyecare Trust</li> <li>Fight for Sight</li> <li>Macular Society</li> <li>National Federation of the Blind of the UK</li> <li>Network of Sikh Organisations</li> <li>Organisation of Blind African Caribbeans</li> <li>Retina UK</li> <li>Royal National Institute of Blind People</li> <li>SeeAbility</li> <li>Sense</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Thomas Pocklington Trust</li> </ul>	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Wales Council for the Blind</li> <li>Welsh Government</li> <li>Welsh Health Specialised Services Committee</li> </ul>
<ul> <li>Healthcare professional groups</li> <li>Association of Optometrists</li> <li>British and Eire Association of Vitreoretinal Surgeons</li> <li>British and Irish Orthoptic Society</li> <li>British Geriatrics Society</li> <li>British Ophthalmic Anaesthesia Society</li> <li>College of Optometrists</li> <li>Optical Confederation</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Ophthalmologists</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> </ul>	<ul> <li>Comparator companies</li> <li>Bayer (aflibercept)</li> <li>Biogen (ranibizumab)</li> <li>Genus Pharmaceuticals (ranibizumab)</li> <li>Novartis (ranibizumab, brolucizumab)</li> <li>Roche (faricimab)</li> <li>Teva UK (ranibizumab)</li> </ul> Relevant research groups <ul> <li>Cochrane Eyes and Vision group</li> <li>Cochrane UK</li> <li>Eye Hope</li> <li>Genomics England</li> <li>Institute of Ophthalmology, University College London</li> <li>MRC Clinical Trials Unit</li> </ul>

Final stakeholder list for the evaluation of bevacizumab gamma for treating wet age-related macular degeneration [ID6320]



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul><li>Royal Society of Medicine</li><li>UK Clinical Pharmacy Association</li></ul>	<ul><li>National Eye Research Centre</li><li>National Institute for Health Research</li></ul>
Others  Department of Health and Social Care  NHS England	<ul><li>Associated Public Health groups</li><li>Public Health Wales</li><li>UK Health Security Agency</li></ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

## **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

Final stakeholder list for the evaluation of bevacizumab gamma for treating wet age-related macular degeneration [ID6320]





All non-company commentators are invited to nominate clinical or patient experts.